β-Arrestin2 Contributes to Cell Viability and Proliferation via the Down-Regulation of FOXO1 in Castration-Resistant Prostate Cancer

Journal of Cellular Physiology

Volumn 230, Issue 10, 2015, Pages 2371-2381

  Duan, Xiaolu ^a   Kong, Zhenzhen ^a   Liu, Yang ^a   Zeng, Zhiwen ^a   Li, Shujue ^a   Wu, Wenqi ^a   Ji, Weidong ^a   Yang, Bicheng ^a   Zhao, Zhijian ^a   Zeng, Guohua ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; PROTEASOME; PROTEIN KINASE B; SOMATOMEDIN; TRANSCRIPTION FACTOR FKHR; ANDROGEN; ANDROGEN RECEPTOR; BETA ARRESTIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; RETINA S ANTIGEN;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROGENS; ARRESTINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84932618738     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24963     Document Type: Article

References (47)

1. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. 2005. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273.
2. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868.
3. Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R, Burchardt M. 2003. The androgen receptor in hormone-refractory prostate cancer: Relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 23:1095-1102.
4. DeFea KA. 2011. Beta-arrestins as regulators of signal termination and transduction: How do they determine what to scaffold?. Cell Signal 23:621-629.
5. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R, Nawata H. 2007. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282:7329-7338.
6. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
7. Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H. 2006. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281:19009-19018.
8. Fu Z, Tindall DJ. 2008. FOXOs, cancer and regulation of apoptosis. Oncogene 27:2312-2319.
9. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H. 2009. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 69:8386-8394.
10. Gan L, Zheng W, Chabot JG, Unterman TG, Quirion R. 2005. Nuclear/cytoplasmic shuttling of the transcription factor FoxO1 is regulated by neurotrophic factors. J Neurochem 93:1209-1219.
11. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, Larsson O. 2005. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 280:24412-24419.
12. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, Lefkowitz RJ, Larsson O. 2007. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 282:11329-11338.
13. Grossmann ME, Huang H, Tindall DJ. 2001. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
14. Hu S, Wang D, Wu J, Jin J, Wei W, Sun W. 2013. Involvement of beta-arrestins in cancer progression. Mol Biol Rep 40:1065-1071.
15. Huang H, Muddiman DC, Tindall DJ. 2004. Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem 279:13866-13877.
16. Huang H, Tindall DJ. 2007. Dynamic FoxO transcription factors. J Cell Sci 120:2479-2487.
17. Huang H, Tindall DJ. 2011. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 1813:1961-1964.
18. Jacome-Pita F, Sanchez-Salas R, Barret E, Amaruch N, Gonzalez-Enguita C, Cathelineau X. 2014. Focal therapy in prostate cancer: The current situation. Ecancermedicalscience 8:435.
19. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
20. Kommaddi RP, Shenoy SK. 2013. Arrestins and protein ubiquitination. Prog Mol Biol Transl Sci 118:175-204.
21. Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ. 2009. Arrestin development: Emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 17:443-458.
22. Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC, Benovic JL, Daaka Y. 2009. Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A 106:9379-9384.
23. Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE. 2007. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol 38:1501-1507.
24. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. 2003. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23:104-118.
25. Lodeiro M, Theodoropoulou M, Pardo M, Casanueva FF, Camina JP. 2009. C-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and -dependent mechanisms. PLoS ONE 4:e4686.
26. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G. 2009. Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 457:1146-1149.
27. Ma L, Pei G. 2007. Beta-arrestin signaling and regulation of transcription. J Cell Sci 120:213-218.
28. Modur V, Nagarajan R, Evers BM, Milbrandt J. 2002. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277:47928-47937.
29. Nakae J, Barr V, Accili D. 2000. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J 19:989-996.
30. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. 2000. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969-8982.
31. Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, Kuro-O M, Rothermel BA, Hill JA. 2007. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 104:20517-20522.
32. Pienta KJ, Bradley D. 2006. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665-1671.
33. Pollak M. 2008. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22:625-638.
34. Povsic TJ, Kohout TA, Lefkowitz RJ. 2003. Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278:51334-51339.
35. Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM. 2008. Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 180:5699-5706.
36. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. 2010. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CX CR7. Proc Natl Acad Sci USA 107:628-632.
37. Schachter TN, Shen T, Liu Y, Schneider MF. 2012. Kinetics of nuclear-cytoplasmic translocation of Foxo1 and Foxo3A in adult skeletal muscle fibers. Am J Physiol Cell Physiol 303:C977-C990.
38. Song G, Ouyang G, Bao S. 2005. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59-71.
39. Tang ED, Nunez G, Barr FG, Guan KL. 1999. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274:16741-16746.
40. Wang P, DeFea KA. 2006. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 45:9374-9385.
41. Wang P, Kumar P, Wang C, Defea KA. 2007. Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins. Biochem J 408:221-230.
42. Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G. 2006. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 7:139-147.
43. Weeks KR, Dwyer DS, Aamodt EJ. 2011. Clozapine and lithium require Caenorhabditis elegans beta-arrestin and serum- and glucocorticoid-inducible kinase to affect Daf-16 (FOXO) localization. J Neurosci Res 89:1658-1665.
44. Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D. 2008. Forkhead box-O transcription factor: Critical conductors of cancer's fate. Endocr Relat Cancer 15:917-929.
45. Wu W, Kong Z, Duan X, Zhu H, Li S, Zeng S, Liang Y, Iliakis G, Gui Z, Yang D. 2013. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. Biochem Biophys Res Commun 442:127-132.
46. Yan L, Lavin VA, Moser LR, Cui Q, Kanies C, Yang E. 2008. PP2A regulates the pro-apoptotic activity of FOXO1. J Biol Chem 283:7411-7420.
47. Zhao M, Zhou G, Zhang Y, Chen T, Sun X, Stuart C, Hanley G, Li J, Zhang J, Yin D. 2009. Beta-arrestin2 inhibits opioid-induced breast cancer cell death through Akt and caspase-8 pathways. Neoplasma 56:108-113.